Overview

Company name	TMRC Co., Ltd.
Location of head office	6-3 Nibanchou, Chiyoda-ku, Tokyo, JAPAN
President and CEO	Hisao Ekimoto
Established	January 2002
Capital	50,000,000 yen (as of Apr 01, 2010)
Banks	Mitsui-Sumitomo Bank Bank of Tokyo-Mitsubishi UFJ Mitsubishi UFJ Trust and Banking
No. of employees	12 (as of Apr 01, 2010)

Operation sites

Head Office	Nibanchou Sankyou Bldg., 6-3 Nibanchou, Chiyoda-ku, Tokyo, 102-0084 TEL: 03-5215-2810 FAX: 03-3265-8780

Contact

History

2002	January	Established in Minato-ku, Tokyo, as a Contract Research Organization (CRO) specializing in the field of cancer, with a capital of 10,000,000 yen.

2004	February	Obtained a license for TM-411 (Tamibarotene), and started an R&D business.
	December	TM-411 for the treatment of multiple myeloma was designated as a supported project by the Pharmaceuticals and Medical Devices Agency (the present National Institute of Biomedical Innovation).

2005	April	Conducted the ninth allocation of new stocks to a third party, increasing the capital to 1,046,200,000 yen.

2006	March	Granted a license for TM-411, for the treatment of acute promyelocytic leukemia (APL), to Choongwae Pharma Corporation (South Korea).
	December	Granted a license for TM-411, for the treatment of acute promyelocytic leukemia (APL), to Innovive Pharmaceuticals, Inc. (North America).

2007	February- May	Conducted the ninth allocation of new stocks to a third party, increasing the capital to 1,447,960,000 yen.
	August	Granted a license for TM-411, for the treatment of hepatocellular carcinoma (HCC), to Zeria Pharmaceutical Co., Ltd. (Japan).
	September	Granted a license for TM-411, for the treatment of acute promyelocytic leukemia (APL), to Innovive Pharmaceuticals, Inc. (Europe).
	November	First patient in a pivotal Phase II clinical trial of TM-411 for the treatment of refractory acute promyelocytic leukemia (APL) in the U.S.A. and Europe.
		Granted a license for TM-411, for the treatment of acute promyelocytic leukemia (APL), to Oder-Made Souyaku Co., Ltd. (China).

2008	August	First patient in Phase I/II clinical trials of TM-411 for the treatment of hepatocellular carcinoma (HCC) in Japan.

2009	February	Started a Phase II clinical trial of TM-411 for the treatment of refractory acute promyelocytic leukemia (APL) in China.
	March	Spun off CRO business and established it as a subsidiary company, then transferred 100% of stocks to Sugi Medical Co., Ltd.
	June	Moved head office to Chiyoda-ku, Tokyo.

*CytRx Corporation (Head office: Los Angeles, California, U.S.A.; President and CEO: Steven A. Krigsman) had acquired Innovive Pharmaceuticals, Inc., licensee of TM-411, a treatment for acute promyelocytic leukemia (APL), for North America and Europe, as of September 19, 2008.

As a result of acquisition, the exclusive license agreement with Innovive Pharmaceuticals, Inc. has been transferred to CytRx Corporation and a clinical trial of TM-411 in the U.S.A. and Europe has been conducted continuously by CytRx Corporation.